MODEL VERDICT
Apyx Medical Corporation (APYX)
Relative Valuation•Peer multiples, Monte Carlo simulation & quality-adjusted fair value
Popular:
Composite score derived from valuation, quality, and risk factors
Quantitative model thresholds · For educational and research purposes only
| Methodology | Fair Value | vs Current | Weight | Quality | Status |
|---|---|---|---|---|---|
| EV To Revenue 78 industry peers | $4.79 | +17.4% | 4% | B | Data |
| Price / Sales 78 industry peers | $5.04 | +23.5% | 3% | B | Model Driven |
| Weighted Output Blended model output | $5.09 | +24.7% | 100% | 56 | UNDERVALUED |
Cross-sectional regression predicting expected multiples based on growth, margins, ROIC, and beta.
| Multiple | Avg | Median | Min | Max | Std |
|---|---|---|---|---|---|
| P/TBV | 4.25 | 3.89 | 2.14 | 8.15 | 2.04 |
| P/B Ratio | 4.25 | 3.89 | 2.14 | 8.15 | 2.04 |
| P/S Ratio | 5.48 | 5.35 | 1.17 | 10.21 | 4.31 |
Based on our peer multiples analysis with 5 valuation metrics, the model estimates APYX's fair value at $5.09 vs the current price of $4.08, implying +24.7% upside potential. Model verdict: Undervalued. Confidence: 56/100. This is a quantitative estimate, not a recommendation.
The blended fair value of $5.09 is calculated using four lenses: industry median multiples (40%), historical multiples (30%), forward estimates (20%), and quality-adjusted multiples (10%). Monte Carlo simulation (10,000 iterations) gives a range of $2.91 (P10) to $7.97 (P90), with a median of $5.36.
APYX's current P/E of -6.2x compares to the industry median of 36.2x (28 peers in the group). This represents a -117.1% discount to the industry. The historical average P/E is N/Ax over 0 years. Signal: Deep Discount.
8 analysts cover APYX with a consensus rating of Buy. The consensus price target is $6.00 (range: $6.00 — $6.00), implying +47.1% upside from the current price. Grade breakdown: Strong Buy (0), Buy (7), Hold (1), Sell (0), Strong Sell (0).
The model confidence score is 56/100, based on: data completeness (6), peer quality (25), historical depth (16), earnings stability (5), and model agreement (4). Cyclicality penalty: -0 points. The model shows moderate agreement across inputs.
The model flags several key risks: (1) Macro/regulatory risks are not captured in this model but remain material.
Peak earnings risk data is not available for APYX.
No. This dashboard is a quantitative research tool for educational and informational purposes only. It is not investment advice, a solicitation, or a recommendation to buy, sell, or hold any security. The operator of this platform is not a registered investment advisor (RIA), broker-dealer, or financial planner. All model outputs, fair value estimates, signals, and scenarios are the result of automated quantitative computations and should not be construed as professional financial guidance. You should consult a qualified, licensed financial advisor before making any investment decisions. Past model performance is not indicative of future results.